Simvastatin Release from Poly(lactide-co-glycolide) Membrane Scaffolds 英文参考文献.docVIP

Polymers 2010, 2, 709-718; doi:10.3390/polym2040709 OPEN ACCESS polymers ISSN 2073-4360 /journal/polymers Article Simvastatin Release from Poly(lactide-co-glycolide) Membrane Scaffolds Hassan Rashidi 1, Marianne J. Ellis 1, Sarah H. Cartmell 2 and Julian B. Chaudhuri 1,* 1 Centre for Regenerative Medicine, Department of Chemical Engineering, University of Bath, Claverton Down, Bath, BA2 7AY, UK; E-Mails: mgxhr@nottingham.ac.uk (H.R.); M.J.Ellis@bath.ac.uk (M.J.E.) 2 School of Materials, Materials Science Centre, University of Manchester, Grosvenor Street, Manchester M13 9PL, UK; E-Mail: sarah.cartmell@manchester.ac.uk (S.H.C.) * Author to whom correspondence should be addressed; E-Mail: J.B.Chaudhuri@bath.ac.uk; Tel.: +44-1225-386349; Fax: +44-1225-385713. Received: 15 November 2010; in revised form: 30 November 2010 / Accepted: 8 December 2010 / Published: 9 December 2010 Abstract: Statins, a group of potent inhibitors of 3-hydroxy-3-methylglutaryl Coenzyme A reductase in cholesterol biosynthesis pathway, have been widely used as a cholesterol lowering drug. The plieotrophic effect of statins on bone metabolism in long-term usage has been begun to be studied during recent years and several in vitro and in vivo studies have demonstrated the ability of statins to promote expression of bone morphogenetic protein-2 (BMP-2), inhibition of osteoclast differentiation and reduction of osteoporotic fractures risk. The high liver specificity and low oral bioavailability of statins, leading to poor peripheral distribution, are the main obstacles to benefit anabolic effects of hydrophobic statins on bone formation. Therefore, developing new administration roots for direct delivery to achieve optimum concentration in the bone microenvironment is of interest. Here we present and compare two approaches of combining statins with bone tissue engineering scaffolds. Simvastatin was combined wit